Floatz logo

Hpc-A

Myeloid Sarcoma

St. Jude Children's Research HospitalPhase 2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Myeloid Sarcoma cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Kura Oncology, Inc.
Phase 3BB
Mitoxantrone
Ruijin Hospital
Phase 3BB
ETOPOSIDE
St. Jude Children's Research Hospital
Phase 3BB
Daunorubicin
Kura Oncology, Inc.
Phase 3BB
Venetoclax
Ruijin Hospital
Phase 2BB

View all 32 →

Same molecule, other indications

Hpc-A is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
myelodysplastic syndromeDormant
CC
Indicative ·
43 / 100
View asset →
chronic myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →